^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

AV-MEL-1

i
Other names: AV-MEL-1, AV MEL 1, autologous dendritic cells loaded with autologous tumor antigens
Associations
Company:
AiVita Biomedical
Drug class:
Immunostimulant
Related drugs:
Associations
over1year
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (clinicaltrials.gov)
P1b, N=20, Recruiting, Aivita Biomedical, Inc. | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2022 --> May 2024
Trial completion date • Trial primary completion date • Checkpoint inhibition • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
AV-MEL-1
over3years
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (clinicaltrials.gov)
P1b, N=20, Recruiting, Aivita Biomedical, Inc. | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2021 --> May 2022
Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
AV-MEL-1
over3years
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (clinicaltrials.gov)
P1b, N=20, Recruiting, Aivita Biomedical, Inc. | Trial completion date: Dec 2023 --> May 2023 | Trial primary completion date: Dec 2021 --> May 2021
Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
AV-MEL-1
almost4years
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (clinicaltrials.gov)
P1b, N=20, Recruiting, Aivita Biomedical, Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
AV-MEL-1
4years
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma (clinicaltrials.gov)
P1b, N=20, Not yet recruiting, Aivita Biomedical, Inc. | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Jun 2020 --> Oct 2021
Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
AV-MEL-1